Skip to main content

People in the News: Andrew Conrad, Robert Hoffman

Premium

SynapDx this week appointed Andrew Conrad to the company's board of directors.

Conrad recently joined Google to participate in its Google X investigative laboratory. He previously served as chief scientific officer and executive vice president of Laboratory Corporation of America and is co-founder of its National Genetics Institute.

Conrad's appointment coincided with Google Ventures' recent investment in SynapDx, which is developing expression array-based tests for autism (see related story, this issue).


CombiMatrix has appointed Robert Hoffman to its board of directors.

Hoffman has been senior vice president of finance and chief financial officer at Arena Pharmaceuticals, a San Diego-based biopharma company, since 1997. He is also a member of the business and financial advisory board of Innovus Pharmaceuticals, a La Jolla, Calif.-based pharmaceuticals company.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.